MedPath

Flatley Discovery Lab LLC

Flatley Discovery Lab LLC logo
🇺🇸United States
Ownership
Private
Established
2009-01-01
Employees
11
Market Cap
-
Website
http://www.flatleydiscoverylab.com

Clinical Trials

9

Active:0
Completed:8

Trial Phases

1 Phases

Phase 1:9

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
9 (100.0%)

A DDI Study of FDL169 and FDL176 in Healthy Subjects

Phase 1
Suspended
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2018-11-28
Last Posted Date
2020-02-05
Lead Sponsor
Flatley Discovery Lab LLC
Target Recruit Count
78
Registration Number
NCT03756922
Locations
🇬🇧

Celerion GB Ltd, Belfast, United Kingdom

A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2018-05-16
Last Posted Date
2018-11-02
Lead Sponsor
Flatley Discovery Lab LLC
Target Recruit Count
11
Registration Number
NCT03527095
Locations
🇬🇧

Quotient Sciences, Ruddington, Nottingham, United Kingdom

A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: FDL176 & FDL169 coadministration
First Posted Date
2018-05-04
Last Posted Date
2018-11-02
Lead Sponsor
Flatley Discovery Lab LLC
Target Recruit Count
16
Registration Number
NCT03516331
Locations
🇬🇧

Quotient Sciences, Nottingham, Ruddington, United Kingdom

An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2018-02-06
Last Posted Date
2018-11-02
Lead Sponsor
Flatley Discovery Lab LLC
Target Recruit Count
11
Registration Number
NCT03424252
Locations
🇬🇧

Quotient Sciences, Nottingham, United Kingdom

A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Placebo
First Posted Date
2017-06-02
Last Posted Date
2018-09-06
Lead Sponsor
Flatley Discovery Lab LLC
Target Recruit Count
109
Registration Number
NCT03173573
Locations
🇦🇺

Wayne Hooper Clinic Clive Berghofer Cancer research Center, Herston, Queenland, Australia

🇦🇺

Mater Hospital, South Brisbane, Queensland, Australia

🇦🇺

Linear Clinical Research, Perth, Western Australia, Australia

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath